ArticleAnalytical sciences : the international journal of the Japan Society for Analytical Chemistry2022
A "turn-on" DNA-scaffolded silver-nanocluster probe for detection of tumor-related mRNA.
Article in Analytical sciences : the international journal of the Japan Society for Analytical Chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel and "turn-on" DNA-silver nanocluster probe (DNA/AgNCs) was developed that can detect the level of breast tumor-related mRNA markers: cyclin D1 mRNA. The fluorescence of DNA/AgNCs probe rendered a "turn-on" response based on the secondary structure changes induced by the target strand. In the presence of target chain, the fluorescence enhances in a concentration-dependent manner, which enables the quantitative detection of analytes. By this method, a detection limit of 2.1 nM and a linear range of 15-125 nM were achieved. In addition, the probe displays excellent discrimination between a perfectly complementary target and single-base mismatch targets, providing an alternative approach for quick and specific recognition and quantification of mRNA or DNA.
Indexed as
Identifiers
35286639What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.